Communicating results in trials with multiple hypotheses or adaptive design features

📅 2026-05-05
📈 Citations: 0
Influential: 0
📄 PDF

career value

177K/year
🤖 AI Summary
This study addresses the underappreciated challenge of estimation and communication following multiplicity adjustment within the frequentist framework in complex clinical trials, where multiple endpoints, interim data looks, or group comparisons often introduce estimation bias and complicate interpretation, thereby undermining transparency in benefit–risk assessment. By integrating advanced methodologies such as adaptive designs and graphical approaches to multiple testing, the work illustrates through concrete examples the limitations of current strategies in conveying trial results meaningfully. The research underscores the need to critically reevaluate prevailing practices and foster interdisciplinary dialogue to enhance both the accuracy of effect estimation and the clarity of result communication, ultimately informing future methodological standards and regulatory guidance.
📝 Abstract
Over time, clinical trials have increasingly incorporated complex design and analysis elements such as interim analyses, adaptations, multiple endpoints, and sophisticated multiplicity schemes for multiple endpoints and/or treatment arms following the paradigm of frequentist inference. In frequentist clinical trials multiplicity can come from (at least) four sources: multiple looks at the data, multiple endpoints, multiple populations, or multiple treatment comparisons. Normally, Type 1 error control across the multiple hypotheses is implemented to control chance of false positive decisions. To achieve this advanced techniques such as adaptive designs or graphical multiple testing procedures have been developed and are used in the design of clinical trials. However, these methods focus on hypothesis testing while subsequent estimation remains crucial to allow for a benefit-risk assessment and further use of the results by various stakeholders. Through examples, we illustrate challenges in estimation and transparent communication. In general, there are no simple solutions to this conceptual and communicational challenge. The purpose of this paper is to generate awareness of these issues and initiate a discussion about how to address them moving forward.
Problem

Research questions and friction points this paper is trying to address.

multiple hypotheses
adaptive design
Type I error control
estimation
transparent communication
Innovation

Methods, ideas, or system contributions that make the work stand out.

adaptive designs
multiple testing
Type I error control
estimation after selection
transparent communication
🔎 Similar Papers
No similar papers found.
E
Elina Asikanius
Finnish Medicines Agency, Turku, Finland
M
Marcel Wolbers
Data Science and Analytics, Roche, Basel, Switzerland
M
Mouna Akacha
Advanced Quantitative Sciences, Novartis Pharma AG, Basel, Switzerland
A
Andreas Brandt
Biostatistics and Special Pharmacokinetics Unit, Federal Institute for Drugs and Medical Devices, Bonn, Germany
B
Benjamin Hofner
Section Data Science and Methods, Paul-Ehrlich-Institut, Langen, Germany; Department of Medical Informatics, Biometry and Epidemiology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
D
Dieter A. Häring
Advanced Quantitative Sciences, Novartis Pharma AG, Basel, Switzerland
K
Kit C. B. Roes
Science Department IQ Health, Biostatistics, Radboud University Medical Center; Medicines Evaluation Board, Netherlands
M
Marc Vandemeulebroecke
Clinical Statistics and Analytics, Bayer BCC AG, Basel, Switzerland; Science Department IQ Health, Biostatistics, Radboud University Medical Center
D
David Wright
Respiratory and Immunology Biometrics and Statistical Innovation, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
J
Joerg Zinserling
Biostatistics and Special Pharmacokinetics Unit, Federal Institute for Drugs and Medical Devices, Bonn, Germany
Kaspar Rufibach
Kaspar Rufibach
Merck KGaA
BiostatisticsClinical trial design